Standard of Practice for Hyperkalemia Treatment in Skilled Nursing Facilities
In a skilled nursing facility, hyperkalemia management should follow a severity-based approach: immediate transfer to emergency care for severe hyperkalemia with ECG changes or K+ >6.5 mEq/L; for mild-moderate hyperkalemia (K+ 5.5-6.5 mEq/L), initiate potassium binders, optimize diuretics if volume overloaded, review and adjust (but avoid discontinuing) RAAS inhibitors, implement dietary modifications, and arrange close monitoring with repeat K+ levels within 1 week. 1
Severity Assessment and Initial Decision-Making
The first critical step is determining whether the patient requires emergency transfer versus SNF-based management:
Transfer to hospital immediately if:
- K+ >6.5 mEq/L
- Any ECG changes (peaked T-waves, widened QRS, loss of P-waves)
- Rapid rise in potassium
- Symptomatic (muscle weakness, palpitations, paresthesias)
Manage in SNF if:
- K+ 5.5-6.5 mEq/L without ECG changes
- Chronic, stable hyperkalemia
- Patient clinically stable
SNF-Based Management Algorithm
Step 1: Confirm True Hyperkalemia
Before initiating treatment, rule out pseudohyperkalemia by:
- Reviewing phlebotomy technique (avoid fist clenching, prolonged tourniquet time)
- Checking for hemolysis
- Repeating the test if any doubt exists
- Remember plasma K+ runs 0.1-0.4 mEq/L lower than serum
Step 2: Identify and Address Reversible Causes
Review for precipitating factors:
- Medications: NSAIDs, potassium supplements, potassium-sparing diuretics, trimethoprim, heparin
- Acute illness: Fever, infection, dehydration, diarrhea (can paradoxically cause hyperkalemia in CKD)
- Dietary indiscretion: Salt substitutes (potassium chloride), high-potassium foods
- Recent medication changes: New RAAS inhibitor or dose increase
Step 3: Pharmacologic Management
Primary treatment: Potassium binders
- Patiromer or sodium zirconium cyclosilicate (SZC) are preferred over older sodium polystyrene sulfonate (SPS)
- SPS carries FDA warning for severe gastrointestinal adverse events including colonic necrosis and 33% mortality rate in some reports
- Newer binders (patiromer, SZC) have demonstrated safety for up to 52 weeks in clinical trials
- These agents allow continuation of RAAS inhibitors, which is critical for mortality reduction
Adjunctive measures based on clinical context:
- Loop diuretics (furosemide): If patient has volume overload and preserved kidney function
- Sodium bicarbonate: Only if concurrent metabolic acidosis present
- Avoid empiric dietary restriction: Evidence for low-potassium diets is limited and may eliminate beneficial plant-based foods; instead focus on reducing non-plant potassium sources
Step 4: RAAS Inhibitor Management - Critical Pitfall
Do NOT automatically discontinue RAAS inhibitors (ACE inhibitors, ARBs, MRAs) in response to hyperkalemia. This is a common error with serious consequences:
- Discontinuation of RAAS inhibitors increases risk of mortality and major adverse cardiovascular events in patients with CKD (eGFR <30) and heart failure
- These medications provide mortality benefit that outweighs hyperkalemia risk when properly managed
- Instead: Treat the hyperkalemia with binders first, allowing continuation of life-saving therapy
- Only consider dose reduction (not discontinuation) if hyperkalemia persists despite binder therapy
- Reinitiate RAAS inhibitors after acute hyperkalemia resolves if previously discontinued
Step 5: Monitoring Protocol
Immediate monitoring:
- Repeat K+ within 24-48 hours after initiating treatment
- Weekly K+ checks until stable in normal range
- Monitor for recurrence: 28-35% of patients experience recurrent hyperkalemia within 12 months
Long-term monitoring:
- K+ levels before starting any RAAS inhibitor
- Within 1 week of RAAS inhibitor initiation or dose increase
- Regular monitoring based on CKD stage and risk factors
- More frequent checks during acute illness, fever, or diarrhea
Common Pitfalls in SNF Setting
Discontinuing RAAS inhibitors reflexively: This increases mortality risk in heart failure and CKD patients who benefit most from these medications 1, 6
Over-relying on dietary restriction: Strict low-potassium diets are difficult to maintain, lack strong evidence, and eliminate heart-healthy foods. Focus dietary counseling on avoiding salt substitutes and excessive supplementation 1, 4
Using sodium polystyrene sulfonate (SPS) as first-line: SPS has serious GI safety concerns and should be avoided when newer binders are available 1
Failing to recognize chronic/recurrent nature: Hyperkalemia often recurs (30-35% within 12 months), requiring ongoing treatment rather than episodic management 3, 7
Inadequate staff education: SNF staff need specific training on when to call providers, recognizing symptoms, and understanding the importance of continuing RAAS inhibitors 8
Real-World Context for SNFs
The SNF population faces unique challenges: elderly patients with multiple comorbidities (CKD, heart failure, diabetes), polypharmacy, and limited access to specialty care. Recent real-world data shows that only 51.5% of eligible patients receive RAAS inhibitors despite having CKD or heart failure, often due to hyperkalemia concerns. Conservative "watch and wait" approaches are common but lead to suboptimal outcomes. 2, 7
The paradigm shift: With availability of effective potassium binders (patiromer, SZC), SNFs can now maintain patients on guideline-directed RAAS inhibitor therapy while controlling hyperkalemia, improving both cardiovascular and renal outcomes. 2, 3, 5